Axsome Therapeutics/$AXSM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Axsome Therapeutics
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Ticker
$AXSM
Sector
Primary listing
Employees
846
Headquarters
Website
AXSM Metrics
BasicAdvanced
$6.1B
-
-$5.06
0.51
-
Price and volume
Market cap
$6.1B
Beta
0.51
52-week high
$139.13
52-week low
$75.56
Average daily volume
514K
Financial strength
Current ratio
1.569
Quick ratio
1.467
Long term debt to equity
198.366
Total debt to equity
297.375
Interest coverage (TTM)
-15.38%
Profitability
EBITDA (TTM)
-199.638
Gross margin (TTM)
91.48%
Net profit margin (TTM)
-49.88%
Operating margin (TTM)
-42.05%
Effective tax rate (TTM)
0.35%
Revenue per employee (TTM)
$590,000
Management effectiveness
Return on assets (TTM)
-21.90%
Return on equity (TTM)
-280.68%
Valuation
Price to revenue (TTM)
12.066
Price to book
83.52
Price to tangible book (TTM)
352.8
Price to free cash flow (TTM)
-49.323
Free cash flow yield (TTM)
-2.03%
Free cash flow per share (TTM)
-2.484
Growth
Revenue change (TTM)
69.83%
Earnings per share change (TTM)
-22.25%
3-year revenue growth (CAGR)
282.87%
3-year earnings per share growth (CAGR)
8.88%
10-year earnings per share growth (CAGR)
24.64%
What the Analysts think about AXSM
Analyst ratings (Buy, Hold, Sell) for Axsome Therapeutics stock.
Bulls say / Bears say
Q2 2025 net product revenue climbed 72% year-over-year to $150 million, led by an 84% rise in AUVELITY sales to $119.6 million and a 35% increase in SUNOSI to $30 million, showing strong commercial performance (Reuters)
The pipeline offers multiple upcoming catalysts, including an sNDA filing for AXS-05 in Alzheimer’s disease agitation in Q3 2025, an NDA for AXS-12 in narcolepsy in Q4 2025, and Phase 3 trial launches for solriamfetol in ADHD and MDD in Q4 2025 (Reuters)
Wall Street analysts have a consensus “buy” rating for AXSM, with a median 12-month price target of $181.50, representing about 43% upside (Reuters)
GAAP net loss of $48 million in Q2 2025 signals ongoing unprofitability even with strong revenue growth (Reuters)
SYMBRAVO's initial launch delivered only $0.4 million in Q2 net product sales, pointing to weak early momentum in the crowded migraine market (Reuters)
Q2 operating expenses reached $186.76 million and surpassed net product revenue of $150 million, emphasizing the company’s high cost structure and longer path to profitability (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.
AXSM Financial Performance
Revenues and expenses
AXSM Earnings Performance
Company profitability
AXSM News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Axsome Therapeutics stock?
Axsome Therapeutics (AXSM) has a market cap of $6.1B as of October 10, 2025.
What is the P/E ratio for Axsome Therapeutics stock?
The price to earnings (P/E) ratio for Axsome Therapeutics (AXSM) stock is 0 as of October 10, 2025.
Does Axsome Therapeutics stock pay dividends?
No, Axsome Therapeutics (AXSM) stock does not pay dividends to its shareholders as of October 10, 2025.
When is the next Axsome Therapeutics dividend payment date?
Axsome Therapeutics (AXSM) stock does not pay dividends to its shareholders.
What is the beta indicator for Axsome Therapeutics?
Axsome Therapeutics (AXSM) has a beta rating of 0.51. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.